CytomX Therapeutics logo

CytomX Therapeutics

CTMX | NASDAQ
Chart Builder DCF Calculator
$1.99
-$0.05 (-2.45%)
At close: Nov 16, 2026, 4:00 PM ET
$2.02
+$0.03 (+1.51%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.45%

Rating

Updated: Nov 16, 2026
31.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #757/1021 (Top 74%)

Key Statistics

Market Data

Market Cap $432.74M
1D Range
1.95 2.08
52W Range
1.95 6.75

Valuation (TTM)

PE -4.42
PB 1.52
EV/EBITDA -1.01

Valuation (NTM)

Forward PE N/A
Forward PEG -0.00
Price Target $6.00
Loading financial charts...

Profile

CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to en...

Sector Healthcare
Industry Biotechnology
Employees 69
IPO Date Oct 8, 2015
Fiscal Year January - December

Latest News

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

8 months ago · globenewswire.com

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
CytomX Therapeutics to Present at Upcoming February Conferences

10 months ago · globenewswire.com

CytomX Therapeutics to Present at Upcoming February Conferences

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.09
Miss -25.16%
REV
$1.69M
Miss -83.73%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
8
Consensus
Buy
Price Target
$6.00
Upside
+201.51%
Buy (8)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.